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We observed that the soluble complement regulators factor H and factor H-like protein were abundantly present in ascites
samples as well as in primary tumours of patients with ovarian cancer. RT–PCR and immunoblotting analyses showed that the
two complement inhibitors were constitutively produced by the ovarian tumour cell lines SK-OV-3 and Caov-3, but not PA-1
or SW626 cells. The amounts of factor H-like protein secreted were equal to those of factor H. This is exceptional, because
e.g. in normal human serum the concentration of factor H-like protein is below 1/10th of that of factor H. In ascites samples
the mean level of factor H-like protein (130+55 mgm l
71) was 5.5-fold higher than in normal human serum
(24+3 mgm l
71). Ovarian tumour cells thus preferentially synthesise factor H-like protein, the alternatively spliced short
variant of factor H. The tumour cells were found to bind both
125I-labelled factor H and recombinant factor H-like protein to
their surfaces. Surprisingly, the culture supernatants of all of the ovarian tumour cell lines studied, including those of PA-1 and
SW626 that did not produce factor H/factor H-like protein, promoted factor I-mediated cleavage of C3b to inactive iC3b.
Subsequently, the PA-1 and SW626 cell lines were found to secrete a soluble form of the membrane cofactor protein
(CD46). Thus, our studies reveal two novel complement resistance mechanisms of ovarian tumour cells: (i) production of
factor H-like protein and factor H and (ii) secretion of soluble membrane cofactor protein. Secretion of soluble complement
inhibitors could protect ovarian tumour cells against humoral immune attack and pose an obstacle for therapy with
monoclonal antibodies.
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Ovarian cancer is the 6th most common malignant neoplasm
among women worldwide, accounting for 4.3% of all female malig-
nancies (Parkin et al, 1993). Despite advances in surgical and
chemotherapeutic regimens and supportive care the overall 5-year
survival is less than 40% (Bjørge et al, 1998). Most ovarian
neoplasms are derived from the surface epithelium of the ovary
and characteristically, the malignant cells remain conﬁned to the
abdominal cavity.
Since ovarian tumours grow within the peritoneal cavity for
prolonged periods local adjuvant therapies could prove useful in
this disease. Potential approaches include immunotherapy with
monoclonal antibodies (mAbs), which could be directly injected
into the peritoneal cavity. The mAbs could bind to individual
tumour cells or their small clusters that remain after removal of
the visible tumour masses. The antibodies, however, should be
sufﬁciently speciﬁc for the tumour cells and recruit appropriate
effector mechanisms including (i) the complement (C) system,
(ii) the antibody-dependent cellular cytotoxicity (ADCC) and
(iii) apoptosis.
Both normal and malignant human cells are protected against
complement-mediated killing by speciﬁc membrane inhibitors.
These include complement receptor 1 (CR1; CD35), membrane
cofactor protein (MCP; CD46), decay accelerating factor (DAF;
CD55) and protectin (CD59) (Morgan and Meri, 1994; Gorter
and Meri, 1999). CR1 and MCP promote factor I (C3b inactivator)
-mediated degradation of C3b (Fearon, 1979; Seya et al, 1986),
whereas DAF and CR1 promote the decay of both the classical
and alternative C pathway C3/C5 convertases (Fearon, 1979;
Nicholson-Weller et al, 1982). CD59 acts by preventing formation
of the membrane attack complex (MAC) on cell membranes (Sugi-
ta et al, 1988; Davies et al, 1989; Meri et al, 1990). CD59 has a key
role in protecting tumour cells against C-mediated destruction
(Hakulinen and Meri, 1994; Junnikkala et al, 1994; Bjørge et al,
1997a,b).
In addition to membrane-bound regulators, soluble factor H is
an efﬁcient regulator of the activity of the alternative pathway
C3 and C5 convertases in plasma and on host cell surfaces (Weiler
et al, 1976; Fearon and Austen, 1977; Whaley, 1980). Down-regula-
tion of C activation by factor H occurs when it binds to host cells
that carry deposited C3b molecules and anionic structures like
sialic acids and glycosaminoglycans (Fearon, 1978; Pangburn and
Mu ¨ller-Eberhard, 1978; Meri and Pangburn, 1990). Factor H is
translated from an mRNA of 4.4 kb to a 150 kDa protein that is
composed of 20 domains called short consensus repeats (SCR)
(Kristensen et al, 1986). In factor H three C3b binding sites and
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mately 600 A ˚ long molecule (Pangburn et al, 1991; Sharma and
Pangburn, 1996; Blackmore et al, 1998; Jokiranta et al, 2000).
Factor H inhibits the alternative C pathway by preventing factor
B binding to C3b, promoting dissociation of the C3bBb enzyme
complex (decay accelerating activity) and by acting as a cofactor
for factor I-mediated inactivation of C3b.
Recent studies have utilised a novel mAb-based immunoassay
(BTA-TRAK) for the detection of urinary bladder cancer
(Heicappel et al, 1999; Raitanen et al, 2001). The mAb used
in the assay recognises factor H or a factor H-related molecule
in the urine of patients with bladder cancer (Kinders et al,
1998). Factor H is the prototype molecule of a family of factor
H-related molecules (Zipfel et al, 1999). The family includes
factor H, factor H-like protein 1 (FHL-1) and factor H-related
proteins (FHRs) 1, 2, 3, 4 and 5. It has been observed recently
that malignant glioblastoma cells produce factor H and FHL-1,
the only two proteins in this family with a clearly documented
C inhibitory function (Gasque et al, 1996; Junnikkala et al,
2000).
FHL-1 is an alternatively spliced product of the factor H gene,
composed of seven N-terminal SCRs of factor H plus an additional
four amino acids (Hellwage et al, 1997; Zipfel and Skerka, 1999).
FHL-1 has essentially the same C inhibiting functions (cofactor
activity, inhibition of factor B binding and decay accelerating activ-
ity) as factor H (Ku ¨hn et al, 1995; Ku ¨hn and Zipfel, 1996; Hellwage
et al, 1997). In the present study our aim was to examine whether
human tumour cells secrete soluble C inhibitors that promote C3b
inactivation. When several cell lines were examined FHL-1 and
factor H were found to be secreted by the ovarian tumour cells
SK-OV-3 and Caov-3 and by the erythroleukaemia cell line
K562. Two ovarian tumour cell lines that did not synthesize factor
H or FHL-1 produced a soluble form of MCP/CD46 with a
partially similar functional proﬁle as factor H. Immunohistological
analyses showed the presence of FHL-1 and factor H on ovarian
tumours in vivo. Factor H and FHL-1 were also abundant in ascites
ﬂuid samples of patients with ovarian cancer. Notably, the level of
FHL-1 was disproportionately high when compared to other biolo-
gical ﬂuids.
These results indicate that ovarian tumour cells produce factor
H/FHL-1, or soluble MCP that may suppress C activation within
the tumour microenvironment.
MATERIALS AND METHODS
Cell lines
The SK-OV-3, Caov-3, PA-1 and SW626 cell lines were origin-
ally obtained from American Type Culture Collection (ATCC,
Manassas, VA, USA). The H2 glioma cell line was established
from a human glioblastoma (Ja ¨a ¨skela ¨inen et al, 1989). Neuronal
cell lines SY5Y and Paju were obtained from Dr Y Shen (Sun
Health Research Institute, Phoenix, AZ, USA) and from Profes-
sor LC Andersson (Haartman Institute, Helsinki, Finland),
respectively. The HF-1 lymphoma cell line was from Dr M
Kaartinen (Haartman Institute, Helsinki, Finland). Other cell
lines listed in Table 2 were from ATCC. All cell lines were
grown in RPMI 1640 medium (Gibco Laboratories, Paisley,
UK) supplemented with 10% (v v
71) heat-inactivated foetal calf
serum (FCS) (Gibco), penicillin (10 U ml), streptomycin
(100 mgm l
71) and 2 mML -glutamine (Nord Cell, Bromma,
Sweden).
Ascites and tumour samples
Ascites ﬂuid (AF) samples (n=16) were obtained in a prospective,
nonselective fashion from previously untreated patients with ovar-
ian cancer at the Department of Obstetrics and Gynecology
(Haukeland Hospital, Bergen, Norway). The samples were
obtained during laparotomy immediately after the peritoneal
cavity was opened. The median age of the patients was 63.5 years
(range from 30–75 years) and the clinical stages were determined
according to the FIGO criteria. AF samples from patients with
liver cirrhosis were collected from patients treated at the Trans-
plantation and Liver Surgery Unit (Helsinki University Hospital,
Helsinki, Finland). Two control samples of ﬂuids from ovarian
follicles were obtained during laparoscopy and draining of follicu-
lar cysts. Ovarian tumour samples (n=25) were obtained from
patients treated at the Department of Obstetrics and Gynecology,
Helsinki University Central Hospital, Helsinki, Finland. The study
protocols were approved by the Ethical Committees of the Hauke-
land Hospital, the Helsinki University Central Hospital and by the
Regional Ethical Committee of Western Norway (Jnr. 234/97-
81.97).
Antibodies
Polyclonal goat anti-factor H antibodies were purchased from
Incstar Co. (Stillwater, MO, USA) or from Calbiochem (La Jolla,
CA, USA). A cell line producing the mAb 196X that binds to
the SCR1 domain of factor H-/FHL-1 was originally from J Tamer-
ius (Quidel Corp., San Diego, CA, USA) and grown as described
(Jokiranta et al, 1996). The mAb VIG8 against the C-terminal
SCR19-20 domain of factor H was obtained from Dr W Prodinger
(Prodinger et al, 1998). The mouse anti-CD46 mAb GB24 (IgG1)
was kindly provided by Dr K Liszewski and Professor JP Atkinson
(Washington University School of Medicine, St. Louis, MO, USA).
An irrelevant mouse IgG (16.1.2 anti-idiotype mAb) was obtained
from Dr M Kaartinen (Haartman Institute, Helsinki, Finland).
RT–PCR analysis
Total RNA was extracted from the cultured ovarian tumour
cells using Trizol LS Reagent (Gibco), as recommended by
the manufacturer. Isopropyl alcohol precipitated RNA was
dissolved in diethylpyrocarbonate-treated water and 1 mgo f
RNA was denatured at 708C for 10 min and then immediately
chilled on ice. The reverse transcriptase reactions were carried
out using RNA in a total volume of 20 ml of reverse transcrip-
tase buffer (Gibco) containing 10 mM dithiotreitol (Gibco),
500 mM dNTP Mix (Pharmacia), 25 mgm l
71 oligo(dT)12-18
(Pharmacia) and 200 U Moloney murine leukaemia virus reverse
transcriptase (Gibco). The reaction was allowed to occur for 1 h
at 378C.
Each PCR reaction was carried out in a 100 ml volume contain-
ing 200 mM dNTP (Pharmacia), 10 pmol of each of the speciﬁc
primers and 2.5 U Taq polymerase (Pharmacia) in a PCR buffer
containing 1.5 mM MgCl2. The samples were denatured at 948C
for 5 min and ampliﬁcation was performed on a Perkin Elmer
GeneAmp PCR System 2400, with denaturation at 948C for
1 min, annealing at 468C for 1 min and extension at 728C for
1 min for 30 cycles. The ﬁnal reaction step was followed by a
10-min extension step at 728C to ensure that the ampliﬁed DNA
was double-stranded. To conﬁrm the absence of contaminants,
negative controls were included in each RT–PCR assay, in which
the RNA samples were replaced by sterile water or the reverse tran-
scriptase was omitted. Ampliﬁed products (10 ml for each PCR
sample) were electrophoresed in parallel with size markers (Gibco)
on a 1% agarose gel. The gels were stained with ethidium bromide
and photographed under UV light. The identities of the PCR
products were conﬁrmed by cloning into the pCRII TA cloning
vector (Invitrogen, Groningen, The Netherlands) and sequencing.
The PCR primers used have been described earlier (Junnikkala et
al, 2000).
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The cell lines were grown in RPMI without FCS for 48 h to obtain
serum-free growth supernatants. The supernatants were concen-
trated 50-fold with the Millipore Ultrafree
1-15 Centrifugal Filter
Device (Bedford, MA, USA). Aliquots of concentrated supernatants,
ascites samples, control samples, NHS and ovarian follicle ﬂuids (all
diluted 1/50 except the supernatants) were electrophoresed on a
10% SDS–PAGE slab gel under nonreducing conditions and trans-
ferred to a nitrocellulose ﬁlter with a pore size of 0.25 mm
(Schleicher & Schuell, Dassel, Germany). After blocking nonspeciﬁc
binding sites with 5% human milk/PBS the ﬁlter was incubated ﬁrst
with an anti-factor H mAb (196X; 5 mgm l
71) overnight at 48C.
After washing peroxidase-conjugated rabbit anti-mouse IgG (diluted
1:2000) (Jackson ImmunoResearch, West Grove, PA, USA) was
added and incubated for 1 h at 228C. For detection of MCP/
CD46 the GB24 mAb was used under similar conditions. The ﬁlters
were washed twice and the bound antibodies were visualised using
an ECL Western blotting kit (Amersham Life Sciences, Amersham,
UK). To estimate the ratios between factor H and FHL-1 in the
samples the immunoblots were analysed by density scanning using
the MacBAS v2.5 programme (Fuji Photo Film Co., Ltd, Japan).
To determine the amounts of factor H and FHL-1 in the ascites
samples an ELISA assay was set up. Microtiter (Nunc Polysorp,
Denmark) plates were coated with a polyclonal goat-anti-human
factor H antibody (Calbiochem, La Jolla, CA, USA) diluted in
carbonate buffer (15 mM Na2CO3,3 5m M NaHCO3, pH 9.6). After
an overnight incubation at +48C the wells were washed with PBS/
Tween 0.05% and nonspeciﬁc binding sites were blocked by incu-
bation with 5% BSA/PBS for 1 h at +378C. The plates were washed
and the samples were applied in appropriate dilutions in 0.5%
BSA/PBS. For a standard curve puriﬁed factor H was added in four
dilutions. After a 2 h incubation the plates were washed and the
monoclonal anti-factor H antibody 196X, 3 mgm l
71 in 0.5%
BSA/PBS, was added and incubated for 3 h at +378C. 196X binds
to SCR1 of both factor H and FHL-1. After washing the secondary
antibody, HRP-conjugated rabbit-anti-mouse IgG (Jackson),
diluted 1:2000 in 0.5% BSA/PBS plus 1% goat serum was added
to the wells. After incubation (2 h, 378C) the plates were washed
and the substrate was added. The colour reaction was stopped with
2M H2SO4 and the absorbances were measured at 492 nm with a
Wallac Victor Multilabel Counter (Wallac, Turku, Finland).
Immunoperoxidase staining of ovarian tumour samples
Serial cryostat sections (4–5 mm) were prepared from fresh ovar-
ian tumour tissue samples that had been frozen in isopentane,
cooled with liquid nitrogen and stored at 7708C. The sections
were allowed to attach to poly-L-lysine coated glass slides, air dried
and ﬁxed in cold (7208C) acetone for 5–10 min. The primary
mAbs (VIG8, 196X, GB24) were applied on the sections at
5 mgm l
71 and incubated overnight at room temperature. An irre-
levant mouse IgG (16.1.2 anti-idiotype mAb) was used as a control.
The sections were washed, incubated for 30 min with HRP-conju-
gated anti-mouse immunoglobulins and stained according to the
manufacturer’s instructions (Vectastain Elite
1 ABC Kit, Vector
Laboratories, Inc., Burlingame, CA, USA). After washing, the
sections were treated with the enzyme substrate aminoethylcarbazol
and counterstained with Mayer’s haematoxylin.
Binding of radiolabelled FHL-1 and factor H to ovarian
tumour cells
Complement factor H (obtained from Calbiochem or puriﬁed as
described) (Meri and Pangburn, 1990) and recombinant FHL-1
(rFHL-1; produced and puriﬁed as earlier described) (Ku ¨hn et al,
1995) were radiolabelled with Na
125I (NEN
TM, Boston, MA,
USA) using an Iodogen method according to the manufacturer’s
instructions. Free
125I was separated from the labelled proteins by
gel ﬁltration through Sephadex G25 (Pharmacia). Speciﬁc activities
of the radiolabelled factor H and rFHL-1 proteins were 6.6610
7
c.p.m. mg
71 and 3.3610
6 c.p.m. mg
71, respectively. Binding of
rFHL-1/factor H to ovarian cells was examined by incubating
triplicate samples of 3610
5 of cells with ﬁxed or varying amounts
of
125I-labelled factor H or FHL-1 as indicated in the respective
ﬁgure legends. In inhibition experiments, 3–100-fold higher
amounts of unlabelled factor H or BSA were incubated with cells
together with
125I-labelled factor H (30 ng). Brieﬂy, the mixtures
were incubated for 1 h at 378C with continuous shaking in a ﬁnal
volume of 120 ml of GVBS (0.1% gelatin, veronal buffered saline,
pH 7.4) diluted 1:3, layered on top of a 250-ml cushion of 20%
sucrose in narrow 0.4-ml test tubes and centrifuged for 5 min at
6100 g. Cell pellets were cut off from the tubes. Both pellets and
supernatants were counted for radioactivity and the binding
percentages were determined as the proportion of cell-bound vs
total radioactivity. All binding experiments were performed twice.
Assay for cofactor activity in ovarian cell growth
supernatants
Complement C3b was puriﬁed as described (Koistinen et al, 1989)
and radiolabelled with
125I to a speciﬁc activity of 1.7610
7 c.p.m.
mg
71. Nonincorporated
125I was separated from the labelled
protein by gel ﬁltration through Sephadex G25 (Pharmacia).
Cofactor activity of cell growth supernatants for C3b cleavage
was examined as described earlier (Junnikkala et al, 2000). Brieﬂy,
10 ml portions of 506-concentrated supernatants were incubated
(2 h, 378C) with 10 ng (10
5 c.p.m.) of
125I-labelled C3b and 3 mg
of factor I (Calbiochem) in a total volume of 30 ml and subjected
to SDS–PAGE and autoradiography. As a control the inactivations
were carried out in the absence of factor I and/or cell growth
supernatant and no
125I-C3b cleavage was observed. In subsequent
experiments the supernatants were ﬁrst preincubated with a poly-
clonal anti-factor H antibody (50 mgm l
71) and/or with the
GB24 anti-MCP (25 mgm l
71) mAb (30 min, 378C) or buffer
(control) before incubation with
125I-C3b and factor I (90 min,
378C). As a positive control
125I-C3b and factor I were incubated
with factor H (25 mgm l
71).
RESULTS
FHL-1 and factor H in ascites ﬂuids of ovarian cancer
patients
The current study was initiated by analysis of soluble C inhibitors
factor H and FHL-1, the short truncated form of factor H, in
ascites ﬂuid (AF) samples of patients with ovarian cancer. Immu-
noblotting with the 196X mAb (recognizing SCR1 of both factor H
and FHL-1) (Figure 1) suggested that most of the ascites samples
(n=16) examined contained higher levels of factor H and especially
of FHL-1 than NHS. Control ﬂuid samples from two ovarian folli-
cle cysts were found to contain similar amounts of factor H and
FHL-1 as NHS (Figure 1B).
In an ELISA assay, employing the 196X mAb, the combined
mean level of factor H and FHL-1 was higher in the cancer patient
AF (758+312 mgm l
71, mean+s.d.; n=16) than in NHS
(461+63 mgm l
71, n=8; Student’s t-test, P50.05) or in AF
samples from liver cirrhosis patients (43+27 mgm l
71, n=6). These
results showed that the potent C inhibitors factor H and FHL-1
were abundantly present in the AF of patients with ovarian cancer
and that the relative proportion of FHL-1 was clearly increased in
the malignant ascites specimens. Using the ELISA assay and quan-
titative density scanning, the mean amounts of FHL-1 were found
to be considerably higher in the AF samples from ovarian cancer
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71; FHL-1/factor H ratio 17.5%) than in NHS
(24 mgm l
71, 5.2%; P50.01), in the AF samples from patients with
liver cirrhosis (52 mgm l
71, 55.0%) or in the follicle ﬂuids
(18 mgm l
71, 5.0%), respectively.
Immunohistochemical detection of FHL-1 and factor H in
ovarian tumours
To investigate the presence of FHL-1 and factor H in ovarian
tumours in vivo, we analysed cryostat sections of serous ovarian
tumours with the VIG8 (detects SCR19-20 of factor H) and 196X
(detects SCR1 of factor H and FHL-1) mAbs and immunoperoxidase
staining. Examples of the stainings are shown in Figure 2. The possi-
ble presence of FHL-1 was judged by a comparison of staining with
the 196X mAb (Figure 2A and B) to staining with the VIG8 mAb. The
staining with 196X showed a similar pattern as VIG8, but a stronger
signal was seen through all layers of the epithelial tumour cells. Factor
H (VIG8 positive staining) was detected mostly in the apical layers of
the tumour cells but to a lesser extent also on the extracellular matrix
(Figure 2C and D). Staining with the GB24 anti-MCP mAb showed a
strong positive staining throughout the tumour cells (Figure 2E and
F). An irrelevant mouse IgG (negative control) showed only a week
nonspeciﬁc staining of ﬁbroblasts, collagen ﬁbrils and blood vessels
in the submucosa (Figure 2G and H). An analysis of a series of serous
ovarian carcinoma samples (n=25) demonstrated that all tumours
expressed factor H/FHL-1. The level of expression, however, ranged
from weak to strong. The expression was weak, considerable or
strong in 11, 12 or 2 samples, respectively. In addition to cellular
staining, factor H/FHL-1 was detected also on the extracellular
matrix. MCP was expressed by all the tumours, expression being
strong in 18 out of the 25 tumours. Factor H/FHL-1 expression
was strongest in tumours with the largest size but otherwise no
apparent correlations to clinical parameters were observed (Table
1). Together with the data obtained from the immunoblotting and
ELISA analyses of ascites samples (Figure 1) the immunohistochem-
ical observations suggested that ovarian tumour cells are capable of
producing FHL-1 and factor H into their microenvironment.
Production of factor H and FHL-1 by ovarian tumour cell
lines
To analyse the production of factor H/FHL-1 by cultured
tumour cells we ﬁrst examined a panel of several cell lines.
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
Ovarian cancer
ascites
N
H
S
S
K
-
O
V
-
3
kDa
194 —
120 —
87 —
64 —
52 —
39 —
26 —
Factor H
FHL-1
1       2        3        4        5       6       7
194 —
120 —
87 —
64 —
52 —
39 —
26 —
kDa
N
H
S
F
o
l
l
i
c
l
e
 
f
l
u
i
d
L
i
v
e
r
 
c
 
i
r
r
h
.
Factor H
FHL-1
B
A
Figure 1 Detection of FHL-1 and factor H in ascites ﬂuids of ovarian
cancer patients. (A) Ascites ﬂuid samples (diluted 1:50) were obtained
from patients with ovarian tumours and NHS from a healthy control sub-
ject. The samples were analysed by SDS–PAGE and immunoblotting using
the 196X mAb that recognises SCR1 of factor H and FHL-1 as the primary
antibody. Histological types of the ovarian tumour samples of the patients
were as follows: 1, serous cystadenocarcinoma; 2, papillary serous cystade-
nocarcinoma; 3, endometrioid adenocarcinoma; 4, undifferentiated adeno-
carcinoma; 5, mucinous adenocarcinoma; 6, serous cystadenoma; 7,
adenocarcinoma from the left ovarian tube. In (B) NHS, an ovarian follicle
ﬂuid sample and ascites from a patient with liver cirrhosis (all diluted 1:50)
were similarly analysed. In all ovarian tumour samples the relative propor-
tional of FHL-1 was higher than in control samples.
Factor H/
FHL-1
Factor H
MCP
Control
Figure 2 Immunohistochemical analysis of the presence of FHL-1 and
factor H in ovarian tumours. Cryostat sections (5 mm) of a serous cystade-
nocarcinoma were ﬁxed and stained with the 196X (A, B) and VIG8 (C,
D) mAb against factor H/FHL-1 SCR1 and factor H SCR19-20, respec-
tively. MCP expression was analysed by the mouse anti-MCP mAb BG24
(E, F) and an irrelevant mouse IgG was used as a negative control (G,
H). The bound mAbs were detected using the Vectastain ABC immuno-
peroxidase staining kit. Original magniﬁcations, 2006 (left row) and
4006 (right row). While combined staining for factor H and FHL-1 oc-
curred throughout the tumour epithelium (A, B) positive staining for factor
H( C, D) was seen most strongly on the outermost mucus layer. Arrows
indicate positively stained areas.
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lines SK-OV-3 and Caov-3, the glioma cell lines H2 and
U138 and the K562 erythroleukaemia/lymphoblast cells constitu-
tively produced factor H and FHL-1 to the culture medium
(Table 2). Two cell lines (U118 and U87) produced only factor
H. This result showed that the production of factor H and
FHL-1 is not a ubiquitous property of all tumour cells, but
restricted to certain tumour cell types. When the ovarian
tumour cells were analysed by RT–PCR the SK-OV-3 and
Caov-3 cell lines were found to express factor H and FHL-1
mRNAs, although the amount of FHL-1 mRNA was relatively
low in the Caov-3 cells. The sizes of factor H (4.4 kb) and
FHL-1 (1.8 kb) mRNAs in these cells were identical to those
detected in human liver tissue. In contrast, the PA-1 and
SW626 cell lines were negative for both factor H and FHL-1
mRNA expression (Figure 3A). All cell lines expressed mRNAs
for the two membrane regulators of complement CD46
(MCP) and CD55 (DAF) which both regulate C activation at
the C3 level (Figure 3A).
In accordance with the RT–PCR analyses, immunoblotting
with the 196X mAb showed that SK-OV-3 and Caov-3 cells
constitutively produced and secreted both the 150 kDa factor
H and the 42 kDa FHL-1 protein to an FCS-free culture
medium during a 48 h incubation. The other two cell lines
PA-1 and SW626 cells remained negative for factor H/FHL-
1 production (Figure 3B). At the protein level both SK-
OV-3 and Caov-3 cells produced approximately similar
amounts of FHL-1 and factor H. This is in contrast with
the situation in serum where the concentration of factor H
is over 10 times higher than that of FHL-1 (Zipfel et al,
1999).
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Table 1 Immunohistochemical detection of factor H/FHL-1 and MCP (CD46) in serous ovarian tumours (n=25)
Expression of
a
Patient Age Tumour size Survival time Factor H/ MCP
No. (years) Stage
b Grade
b (diam. in cm) (years)
c FHL-1 (CD46)
1 49 IIIc 1 425 43.1 +++ +++
2 76 IIc 2 5–10 43.1 + ++
3 44 IIIc 1 410 43.5 ++ ++
4 68 IIIc 3 410 43.0 ++ ++
55 0 I b 1 420 42.4 ++ +++
63 9 I V 1 5 – 1 043.5 + +++
7 70 IIIc 2 5–10 42.5 + +++
8 78 IIIc 3 410 50.5{ ++ +
9 55 IIIc 3 5–10 42.4 + ++
10 7
d 7
d 3 7
d 7
d + +++
11 7
d 7
d 3 7
d 7
d ++ ++
12 68 Ia 1 5–10 42.4 ++ +++
13 54 IIIc 1 415 42.3 +++ +++
14 42 IIIc 1 410 42.3 + +++
15 41 IIIc 3 5–10 2.8{ + +++
16 79 IIIc 3 5–10 50.5{ ++ +++
17 65 IV 4 420 1.4{ ++ ++
18 65 IIIc 3 410 42.0 ++ +++
19 45 IIIb 1 410 7
d ++ +++
20 58 IIIc 2 410 42.1 ++ +++
21 55 IIIc 3 410 7
d ++ +++
22 40 IIIc 1 410 41.7 + +++
23 44 IV 3 410 1.5{ + +++
24 62 IIIc 3 2–5 41.3 + +++
25 7
d 7
d 2 7
d 7
d ++ +++
aThe level of expression is shown as: 7, no expression; +, weak; ++, considerable; +++, strong. An irrelevant mouse IgG (16.1.2 anti-
idiotype mAb) was used as a control. All control stainings were negative (data not shown). The primary mAbs 196X and GB24 were
used for staining of factor H/FHL-1 and MCP, respectively.
bAccording to FIGO classiﬁcation.
cTime from diagnosis. {, deceased.
dInformation not available.
Table 2 Production of complement inhibitors factor H and FHL-1 by
cultured tumour cell lines
Tumour or cell
Cell line type of origin Factor H FHL-1
H2 Glioblastoma +++ ++
U138 7 +++ ++
U118 7 ++ 7
U87 7 + 7
U251 77 7
U373 77 7
SY5Y Neuronal 77
Paju 77 7
SK-OV-3 Ovarian +++ +++
Caov-3 7 ++ +
PA-1 Teratocarcinoma 77
SW626 Ovarian/colonic 77
T47D Breast 77
MCF7 77 7
G361 Melanoma 77
HUVEC Endothelial 77
EA.hy926 Endothelial-like 77
HT1080 Fibrosarcoma 77
HF-1 B-cell lymphoma 77
Jurkat T-cell leukaemia 77
K562 Myelogenous leukaemia ++++ ++++
U937 Histiocytic lymphoma 77
Different types of tumour cells were grown for 48 h in the absence of FCS. Concen-
trated (506) cell culture supernatants were analysed by SDS–PAGE and
immunobloting using the 196X mAb (5 mgm l
71) against SCR1 of factor H and
FHL-1 as a primary antibody. Peroxidase-conjugated rabbit anti-mouse IgG was used
as a secondary antibody. The level of expression is shown as: 7, no expression; +,
weak; ++, considerable; +++, strong; ++++, very strong expression.
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The immunohistochemical evidence of tumour-associated factor
H/FHL-1 suggested that the ovarian tumour cells could carry
surface components that bind factor H and/or FHL-1, proteins
which both have binding sites for glycosaminoglycans and
other polyanions. In accordance, we found that all the ovarian
tumour cell lines SK-OV-3, Caov-3, PA-1 and SW626 bound
both
125I-labelled factor H and FHL-1 to their cell surfaces
(Figure 4A). Binding of factor H was most efﬁcient to the
SK-OV-3 cells and occurred in a saturable manner (Figure
4B). The binding of
125I-factor H could be inhibited maximally
by 70% with unlabelled factor H (Figure 4C). The binding
data indicated that the ovarian cells SK-OV-3, Caov-3, PA-1
and SW626 have the ability to bind soluble factor H and
FHL-1 from the ﬂuid phase even in the absence of initial
C3b deposition.
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Figure 3 Expression of C regulators factor H and FHL-1 by ovarian tu-
mour cell lines. (A) RT–PCR analysis of mRNA expression of FHL-1, fac-
tor H, MCP (CD46) and DAF (CD55) by the cell lines SW626, PA-1, SK-
OV-3 and Caov-3. mRNAs were isolated from the tumour cell lines and
analysed by RT–PCR, b-actin mRNA expression was tested as a positive
control. Factor H and FHL-1 mRNAs were detected in SK-OV-3 and
Caov-3 cells but not in the two other cell lines. (B) Analysis of FHL-1
and factor H protein production by SW626, PA-1, SK-OV-3 and Caov-3
cells. Growth supernatants of cells grown for 48 h in the absence of FCS
were collected and concentrated 50-fold. NHS (2%) was used as a positive
control. The samples were run in SDS–PAGE under nonreducing condi-
tions and analysed by immunoblotting. 196X mAb (5 mgm l
71), which de-
tects both factor H and FHL-1, was used as the primary antibody, and
peroxidase-conjugated rabbit anti-mouse IgG as the secondary antibody.
Molecular weights of the marker proteins are indicated on the left. Note
higher FHL-1/factor H ratios in the ovarian tumour cell supernatants as
compared to NHS.
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Figure 4 Factor H/FHL-1 binding to ovarian tumour cells. (A) Binding of
125I-labelled factor H and FHL-1 to ovarian tumour cells SW626, PA-1, SK-
OV-3 and Caov-3. Cells (93610
5) were incubated with radiolabelled fac-
tor H (30 ng, 6.6610
6 c.p.m. mg
71) or FHL-1 (30 ng, 3.3610
6 c.p.m.
mg
71) for 1 h at 378C in 1:3 GVBS, pH 7.4. The results (mean+s.d.;
n=3) are expressed as the amount of bound protein (ng). A representative
of three experiments with similar results is shown. (B) Dose-response ana-
lysis of binding of
125I-labelled factor H and FHL-1 to SK-OV-3 cells. (C)
Inhibition analysis of binding of
125I-labelled factor H to SK-OV-3 cells. In-
dicated amounts of unlabelled factor H or BSA (up to a 100-fold excess)
were incubated together with
125I-labelled factor H as in (A).
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cell supernatants
Since SK-OV-3 and Caov-3 cells were found to produce and
secrete both factor H and FHL-1 into their growth supernatants
we wanted to study whether they were capable of promoting the
degradation of C3b to iC3b, i.e. whether the secreted proteins acted
as cofactors for factor I. Cofactor activity analysis demonstrated
that the supernatants of all the cell lines, including those of PA-1
and SW626, promoted factor I-mediated cleavage of
125I-labelled
C3b (Figure 5). When the supernatants were preincubated with a
polyclonal anti-factor H antibody the cofactor activities of SK-
OV-3 and Caov-3, but not of PA-1 and SW626 cell supernatants
were clearly reduced. The fact that PA-1 and SW626 cells did
not produce factor H or FHL-1, yet their growth supernatants
promoted C3b degradation suggested that other cofactors for factor
I could be involved. The explanation to this was suggested by
immunoblotting analysis which showed that PA-1 and SW626 cells
produced a soluble form of the membrane cofactor protein (MCP/
CD46) into their growth supernatants (data not shown). The role
of MCP was veriﬁed by studies with the anti-MCP mAb GB24,
which completely blocked the cofactor activities of PA-1 and
SW626 cell supernatants (Figure 5). No CR1, another potential
cofactor candidate for C3b inactivation, was detected in any of
the cell supernatants (data not shown). In summary, the results
indicated that all the four cell lines secreted cofactor activity for
factor I. In two cases (SK-OV-3 and Caov-3) this was mainly
due to factor H and FHL-1 and in the other two cases (PA-1
and SW626) it was due to a soluble form of MCP.
DISCUSSION
In this study, we observed that ovarian tumour cells can secrete
and/or utilise functionally active inhibitors of the cytolytic C
system, factor H and FHL-1. This suggests that ovarian tumours
create a surrounding microenvironment, where ﬂuid phase C acti-
vation may be inhibited. The abundant presence of factor H and
FHL-1 in the AF samples and in the apical layers and extracellular
matrix surrounding the tumour cells of patients with ovarian carci-
noma suggest that C activation is controlled within the peritoneal
cavity. This is one reason to explain why neither the antibody-
initiated classical pathway nor the alternative pathway is effective
in destroying ovarian tumour cells.
We have recently demonstrated that the C resistant H2 glioblas-
toma cell line constitutively produced factor H and FHL-1 and
protected itself against C attack in vitro (Junnikkala et al, 2000).
A survey of several cell lines showed that the production of these
C regulators is not restricted to glioblastomas but occurs also in
ovarian tumour cells and in the K562 erythroleukaemia cells (Table
2).
There is already some evidence for the role of factor H in the
resistance of nucleated tumour cells against C damage initiated
by the classical pathway (Ollert et al, 1995). In accordance with
our studies, certain glioma and neuroblastoma cells have been
shown to express factor H mRNA (Gasque et al, 1992, 1996)
and a human oligodendrocyte cell line (HOG) secreted factor H
when stimulated with interferon-g (Gasque and Morgan, 1996).
There is also evidence that factor H can bind to polymorphonuc-
lear leucocytes (PMN), U937 cells and B lymphoblastoid Raji cells
(Erdei and Sim, 1987; Avery and Gordon, 1993; DiScipio et al,
1998). However, the current study is the ﬁrst one to propose such
a role for FHL-1 and to show the presence of FHL-1 in samples
from patients with ovarian tumours. Since FHL-1 shares the C
regulatory functions with factor H (Friese et al, 1999b) it can be
proposed that it perhaps controls C activation within the microen-
vironment of tumour cells.
The amounts of FHL-1 in ascites samples from ovarian cancer
patients were found to be considerably higher than in NHS or in
ascites from a patient with liver cirrhosis (Figure 1). The fact that
they were also higher in AF than in ovarian follicle ﬂuids suggests
that production of FHL-1 is related to malignancy rather than to
the source of cells. As the patients (n=16) from whom the samples
were obtained had different types of ovarian tumours and samples
from all of them were positive for FHL-1 it is likely that the
production of FHL-1 is a general feature of ovarian tumours.
However, there were up to 3–4-fold differences in the amounts
of factor H/FHL-1 between the AF samples of ovarian cancer
patients. Whether these are individual differences between the
patients or whether a high expression level is related to certain
ovarian tumour types remain to be further studied. Since ascites
represents a separate ﬂuid compartment within the peritoneal
cavity, and the tumour cells are in direct contact with the AF, it
is probable that FHL-1 and factor H synthesised by the tumour
cells are concentrated into the peritoneal cavity and may protect
tumour cells locally against C-mediated damage.
To further investigate the expression of FHL-1 and factor H in
vivo we performed immunohistological analysis of tumour tissue
samples obtained from 25 patients with serous cystadenocarcino-
ma, the most common type of malignant ovarian neoplasm
(Christopher, 1994). Table 1 summarizes the expression levels of
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Figure 5 Cofactor activity of the ovarian cell growth supernatants for
factor I-mediated cleavage of
125I-labelled C3b. Cell supernatants (concen-
trated 50-fold) were ﬁrst preincubated with or without polyclonal anti-fac-
tor H (50 mgm l
71) or the GB24 anti-MCP (25 mgm l
71) antibody (378C,
30 min) and then for 90 min at 378C with
125I-labelled C3b and factor I
(25 mgm l
71). In the positive controls
125I-C3b and factor I were incubated
with factor H (25 mgm l
71). The mixtures were analysed by SDS–PAGE
and autoradiography under reducing conditions. The protein compositions
in the mixtures are marked beneath the lanes. The a'-chain of
125I-C3b be-
comes cleaved into fragments with apparent Mrs of 68, 46 and 43 kDa. Be-
cause of the relatively high concentration of factor H in the positive control
(second lane from the left) the second factor I-mediated cleavage had fully
converted the 46 kDa fragment into the 43 kDa a'-chain fragment. The co-
factor activity of the SW626 and PA-1 supernatants could be inhibited with
the anti-MCP mAb whereas the activities of the SK-OV-3 and Caov-3
supernatants were inhibited with the polyclonal anti-factor H antibody.
The results indicate that all the ovarian cell supernatants have cofactor ac-
tivity for C3b cleavage. In SK-OV-3 and Caov-3 cells this is due to function-
ally active H/FHL-1, whereas in the SW626 and PA-1 cell supernatants it is
due to soluble MCP.
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MCP was strong in most of the tumours. This indicates that MCP
is a common, strongly expressed regulator in ovarian tumours. The
staining intensity of factor H/FHL-1 varied from weak to strong
being considerable in most of the cases. Staining with the 196X
mAb that detects both factor H and FHL-1 showed a stronger posi-
tive signal (Figure 2A and B) than staining with the VIG8 mAb,
which detects only factor H (Figure 2C and D). Staining for factor
H/FHL-1 was seen in both the apical tumour cell layers and in the
intercellular spaces. It is thus likely that both factor H and FHL-1
bind to the apical epithelium. The proteins can be directly
produced by the tumour cells and/or they can inﬁltrate from the
blood to the ascites and then bind to the apical surfaces of tumour
cells. Since both proteins were found in the apical tumour cell
layers (Figure 2A–D), it can be suggested that these layers form
a protective barrier against C attack. The data on immunoblotting
(Figure 1) and ELISA analysis of ascites samples further supported
the immunohistological results and indicated that the ovarian
tumour cells are capable of producing FHL-1 and factor H in vivo.
RT–PCR (Figure 3A) and immunoblotting (Figure 3B) experi-
ments showed that the SK-OV-3 and Caov-3, but not the PA-1 and
SW626, ovarian tumour cell lines produced factor H and FHL-1
mRNA and protein. The expression of factor H/FHL-1 was consti-
tutive and did not require exogenous stimuli. There is evidence
that this is the case also with human ﬁbroblasts and HUH7 hepatic
(Friese et al, 1999a), HTB153 rhabdomyosarcoma (Legoedec et al,
1995) and CB193 astroglioma cells (Gasque et al, 1995). These
results suggest that, although not ubiquitous, the production of
factor H and FHL-1 may be a relatively common C resistance
mechanism of tumours of different origin than previously thought.
The relatively high proportion of FHL-1, as compared to factor
H, in the SK-OV-3 and Caov-3 cell growth supernatants (Figure
3B) suggested that FHL-1 may have a role in the control of the
alternative C pathway activation against tumour cells. The average
FHL-1/factor H ratio in the ovarian cancer patient AF samples was
found to be over three-fold higher than in NHS or in follicle ﬂuids
(17.5% vs 5.2% or 5.0%, respectively). FHL-1 thus appears to be
preferentially produced by malignant cells also in vivo.
SK-OV-3, Caov-3, PA-1 and SW626 ovarian tumour cells were
found to bind both
125I-labelled factor H and FHL-1 to their cell
surfaces (Figure 4). This suggested that the surfaces of cultured
ovarian cells have structures that bind factor H and FHL-1 from
the surrounding medium or from plasma. The relatively high
number of factor H and FHL-1 molecules bound to the tumour
cells, approximately 10
4 and 5610
4 per cell, respectively, is prob-
ably due to an abundancy of low afﬁnity receptors, e.g.
glycosaminoglycans or sialic acid-type polyanions on the cell
surfaces.
To verify that factor H and FHL-1, that are produced by the SK-
OV-3 and Caov-3 cells and bind to them, were functionally active
we tested whether the growth supernatants of these cells could
promote factor I-mediated cleavage of
125I-labelled C3b to its inac-
tive form iC3b. Both SK-OV-3 and Caov-3 cell supernatants
promoted factor I-mediated cleavage of C3b to iC3b (Figure 5).
This activity was inhibited by a polyclonal antibody against factor
H. Surprisingly, also the supernatants of PA-1 and SW626 cells
promoted C3b cleavage. The reason for this was revealed when
we found out that these cell lines produced soluble MCP (Hakuli-
nen et al, unpublished results) and that it was possible to inactivate
the cofactor activity with the GB24 anti-MCP mAb (Figure 5).
Earlier, soluble forms of MCP have been detected in body ﬂuids
(Hara et al, 1992) and also in cancer patients’ sera that contained
increased amounts of the 56 and 47 kDa soluble forms of MCP
(Seya et al, 1995).
The different behaviour of PA-1 and SW626 cells may be related
to their possibly different origins as compared to the SK-OV-3 and
Caov-3 cells. PA-1 is a teratocarcinoma cell line and for SW626,
although it has been isolated from an ovarian tumour, recent
observations suggest that it could originate from a colon tumour
metastasis (Furlong et al, 1999).
Taken together, our observations indicate that the ovarian
tumour cell lines have similar strategies, but different factors, to
suppress C activation on their surfaces. In addition to the cell
membrane regulators, it is possible that factor H, FHL-1 and solu-
ble MCP may restrict C activation and prevent deposition of the
terminal C components to the surfaces of tumour cells. Production
of C inhibitors by tumour cells can be an important factor also
when tumour treatment with C activating mAbs is considered
(Gorter and Meri, 1999; Harjunpa ¨a ¨ et al, 2000). In the case of
ovarian carcinoma, the presence of the tumour cells within the
peritoneal cavity makes them an attractive target for local immu-
notherapy. Such a therapy could be of considerable beneﬁt if the
activity of the C system within the peritoneal space and around
the tumours could be enhanced, e.g. by temporarily blocking C
inhibitors.
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